MODERN APPROACH TO THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS
Abstract
Infection caused by Clostridium difficile (CDI) occurs as a result of an imbalance of bacteria in the intestinal tract mainly due to previous exposure to wide-spectrum systemic antibiotics. Nowadays, it is recognized as one of the most frequent infections acquired in hospitals. Contemporary clinicians often face an increased incidence of fulminant and recurrent CDIs that are accompanied by a number of colectomies, prolonged stay in hospitals, fatal outcome, and rising healthcare costs. Traditional antibiotics for CDI, such as metronidazole, vancomycin or fidaxomicin, have been linked to certain treatment limitations in previous studies. Thus, the aim of this narrative mini literature review was to critically evaluate the efficiency of each of the recommended modern therapy modalities for CDI, as well as the frequency and severity of adverse events associated with their use.
Based on current knowledge, the range of standard antibiotics approved for treatment of initial or recurrent CDI remains quite limited. Regardless of the severity of CDI, oral or rectal vancomycin should be considered as the first-line therapeutic option in adults and children, while fidaxomicin or metronidazole could be an appropriate alternative. The other potentially effective antimicrobials against CDI, such as rifaximin, nitazoxanide, fusidic acid, tigecycline, bacitracin and use of probiotics cannot be advised as the therapy of choice, as they did not provide any advantage over vancomycin or fidaxomicin in prior investigations. In an attempt to solve the problem of recurrent CDI events, which is one of the most important challenges facing health professionals today, adjunct use of human monoclonal antibody against toxin B (bezlotoxumab) or instillation of normal colonic bacteria obtained from healthy donor into patient’s intestine (Fecal Microbiota Transplantation), could be effective and safe approach where available. Besides clinical development of innovative therapy for CDI, such as new antibiotics and vaccines, primary focus should be on effective prevention of this infection, in terms of improving rational use of broad-spectrum systemic antibiotics and proton pump inhibitors
References
McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66(7): e1-e48.
European Centre for Disease Prevention and Control. European Centre for Disease Prevention and Control. Clostridium difficile infections. In: ECDC. Annual epi-demiological report for 2016. Stockholm: ECDC; 2018.
Vindigni SM, Surawicz CM. C. difficile Infection: Chan-ging Epidemiology and Management Paradigms. ClinTranslGastroenterol 2015; 6:e99.
Evans CT, Safdar N. Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clin Infect Dis 2015; 60 Suppl 2: S66-71.
Petrosillo N, Granata G, Cataldo MA. Novel Antimicro-bials for the Treatment of Clostridium difficile Infection. Front Med (Lausanne) 2018; 5: 96.
Kociolek LK, Gerding DN. Breakthroughs in the treat-ment and prevention of Clostridium difficile infections. Nat Rev GastroenterolHepatol 2016; 13: 150-60.
Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for pre-vention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376: 305-17.
de Bruyn G, Saleh J, Workman D, et al; H-030-012 Clinical Investigator Study Team. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized phase 2 clinical trial. Vaccine 2016; 34: 2170-8.
Sheldon E, Kitchin N, Peng Y, et al. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine 2016; 34: 2082-91.
Bezay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine 2016; 34: 2585-92.
Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. ClinMicrobiol Infect 2014; 20(Suppl 2): 1–26.
Trubiano JA, Cheng AC, Korman TM, et al. Australasian society of infectious diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 2016; 46(4): 479–93.
Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3:CD004610.
Ooijevaar RE, van Beurden YH, Terveer EM, et al. Update of treatment algorithms for Clostridium difficile infection. ClinMicrobiol Infect 2018; 24(5): 452-62.
Di X, Bai N, Zhang X, et al. A meta-analysis of metroni-dazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015; 19(4): 339-49.
Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55(Suppl 2): S162–9.
Biswas JS, Patel A, Otter JA, et al. Reduction in Clostri-dium difficile environmental contamination by hospi-talized patients treated with fidaxomicin. J Hosp Infect 2015; 90(3): 267–70.
Burton HE, Mitchell SA, Watt M. A Systematic Litera-ture Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. Pharma-coeconomics 2017; 35(11): 1123-40.
Marković V, Kostić M, Iličković I, Janković SM. Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition. Value Health Reg Issues 2014; 4: 87-94.
Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent C. difficile infection in pati-ents at increased risk for recurrence. Clin Infect Dis 2018. doi: 10.1093/cid/ciy171. [Epub ahead of print]
Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics : Targets & Therapy 2018; 12: 11-21.
Lee Y, Lim WI, Bloom CI, Moore S, Chung E, Marzella N. Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. Pharmacy and Therapeutics 2017; 42(12): 735-8.
Cammarota G, Ianiro G, Tilg H, et al; European FMT Working Group. European consensus conference on faecalmicrobiota transplantation in clinical practice. Gut 2017; 66(4): 569-580.
Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostri-dium difficile Infection. Chest 2018; 153(1): 266-77.
van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium diffi-cile. N Engl J Med 2013; 368: 407–15.
Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Ga-stroenterol 2012; 107: 1079–87.
Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761–7.
Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recur-rent Clostridium difficile infection. Aliment Pharma-colTher 2015; 41: 835–43.
Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a ran-domized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515–22.
Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315: 142–9.
Kelly CR, Khoruts A, Staley C, et al. Effect of fecal mic-robiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016; 165: 609–16.
Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal micro-biome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 2013; 19: 22–6.
Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J ClinGastroenterol 2013; 47(8): 735-7.
Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. ClinGastroenterolHepatol 2016; 14: 1433–8.